{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:50:25Z","timestamp":1772578225447,"version":"3.50.1"},"reference-count":53,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Clinical stage I (CS I) testicular non-seminomatous germ cell tumours (NSGCT) are highly curable. Following orchidectomy, a risk-adapted approach using active surveillance, nerve-sparing retroperitoneal lymph node dissection (RPLND) and primary chemotherapy is recommended by the current guidelines. CS I is defined as showing negative values for tumour markers (or values declining to their half-life following orchidectomy) and negative imaging studies of the chest, abdomen and retroperitoneum. Active surveillance can be performed in low- and high-risk NSGCT with an anticipated relapse rate of about 15% and 50%, respectively. The majority of patients will relapse with good and intermediate prognosis tumours, which have to be treated with 3 to 4 cycles of chemotherapy. About 25-30% of these patients will have to undergo postchemotherapy (PC) RPLND for residual masses. Primary chemotherapy with 1-2 cycles of cisplatin, etoposide, bleomycin (PEB) is a therapeutic option for high-risk CS I NSGCT associated with a recurrence rate of only 2-3% and a minimal acute and long-term toxicity rate. Nerve-sparing RPLND, if performed properly, will cure about 85% of all high-risk patients with CS I NSGCT without the need for chemotherapy. PC-RPLND plays an integral part of the multimodality treatment in patients with advanced testicular germ cell tumours (TGCT). According to current guidelines and recommendations, PC-RPLND in advanced seminomas with residual tumours is only indicated if a positron emission tomography scan performed 6-8 weeks after chemotherapy is positive. In non-seminomatous TGCT, PC-RPLND is indicated for all residual radiographical lesions with negative or plateauing markers. Loss of antegrade ejaculation represents the most common long-term complication, which can be prevented by a nerve-sparing or modified template resection. The relapse rate after PC-RPLND is around 12%; however, it increases significantly to about 45% in cases with redo RPLND and late relapses. Patients with increasing markers should undergo salvage chemotherapy. Only select patients with elevated markers who are thought to be chemo-refractory might undergo desperation PC-RPLND if all radiographically visible lesions are completely resectable. PC-RPLND requires a complex surgical approach and should only be performed in experienced, tertiary referral centres.<\/jats:p>","DOI":"10.1159\/000489508","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T21:01:16Z","timestamp":1526590876000},"page":"370-378","source":"Crossref","is-referenced-by-count":19,"title":["Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer"],"prefix":"10.1159","volume":"41","author":[{"given":"Axel","family":"Heidenreich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Paffenholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.044"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt304"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.1.16"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.11.1762"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.3.CO;2-F"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.169"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2004.04.004"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.261"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199511000-00049"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000165163.03805.37"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.08.032"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.05.036"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.132"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199510000-00031"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42869-2"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.08.022"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950501)75:9<2244::AID-CNCR2820750909>3.0.CO;2-I"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199701000-00050"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000060960.18092.54"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0808"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.01.002"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.014"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-006-0060-8"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000119121.36427.09"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.184"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw605"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000060121.33899.4b"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-014-3708-9"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.188"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2004.07.012"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.0755"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.0714"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.08.024"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00517-5"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200105000-00027"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.045"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.03.039"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1343::AID-CNCR18>3.0.CO;2-6"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10440"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1998.00497.x"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22898"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13844"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.027"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-014-1240-6"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(93)90330-D"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000052372.06901.de"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(03)00579-X"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.08.012"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200008000-00026"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.684"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199803000-00018"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.07.050"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000120141.89737.90"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/489508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/489508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:30:15Z","timestamp":1745425815000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000489508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,5,29]]}},"URL":"https:\/\/doi.org\/10.1159\/000489508","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}